[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"albuminuria\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:albuminuria":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,40,71,98,139,168,199,263,299,327],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100477526","phase-4-effect-of-montelukast-on-kidney-and-vascular-function-in-type-1-diabetes-100477526",false,"NCT05498116","Effect of Montelukast on Kidney and Vascular Function in Type 1 Diabetes","Inclusion Criteria:\n\n* Age 18-80 years\n* Type 1 diabetes for at least 5 years\n* Urine albumin to creatinine ratio 30-5000 mg\u002Fg on first morning void\n* eGFR 30-89 ml\u002Fmin\u002F1.73m2 at time of screening\n* Blood pressure \\\u003C140\u002F90 mm Hg prior to randomization\n* Use of angiotensin converting enzyme inhibitor or angiotensin receptor blocker with stable dose for 4 weeks\n* BMI \\\u003C 40 kg\u002Fm2 (FMDBA measurements can be inaccurate in severely obese patients).\n* Stable anti-hypertensive regimen for at least one month prior to randomization\n* Stable regimen of insulin delivery, i.e. automated insulin delivery (AID) system or multiple daily injections) 4 weeks prior to randomization\n* Sedentary or recreationally active (≤2 days of vigorous aerobic exercise as vigorous exercise may affect vascular function measurements)\n* Able to provide consent\n\nExclusion Criteria:\n\n* Significant comorbid conditions that lead the investigator to conclude that life expectancy is less than 1 year\n* Uncontrolled hypertension\n* Factors judged to limit adherence to interventions\n* Anticipated initiation of dialysis or kidney transplantation within 6 months\n* Current participation in another research study\n* Pregnancy or planning to become pregnant or currently breastfeeding\n* Allergy to aspirin\n* Severe hepatic impairment (Child-Pugh Class C)\n* History of major psychiatric disorder\n* Use of inhaled or systemic corticosteroids or long-acting beta agonists (higher risk of neuropsychiatric reaction)\n* Penicillin allergy\n* Iodine allergy\n* Shellfish allergy\n* Current use of phenobarbital, rifampin or carbamazepine","ALL","18 Years","80 Years",{"count":19,"type":20},50,"ESTIMATED","INTERVENTIONAL",[23],"PHASE4","Kidney disease is a common problem among people with type 1 diabetes and can lead to disability, dialysis, and early death. Inflammation plays a key role in the development of kidney disease in type 1 diabetes and targeting leukotrienes, inflammatory chemicals the body releases in response to allergic reactions, may represent a promising therapy to slow the progression of diabetic kidney disease. The current proposal will investigate whether montelukast, a leukotriene blocker, lowers increased levels of protein in the urine (an early marker of diabetic kidney disease), and improves kidney and cardiovascular function in people with type 1 diabetes and kidney disease.",[26],"Albuminuria","RECRUITING","2026-06-29",{"date":30,"type":31},"2026-06-30","ACTUAL",{"date":33,"type":31},"2023-01-26",{"date":35,"type":20},"2027-04",{"name":37,"class":38},"University of Colorado, Denver","OTHER",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":47,"targetDuration":4,"studyType":21,"phases":49,"briefSummary":50,"conditions":51,"keywords":54,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":70},"100643970","phase-4-finerenone-for-regression-of-albuminuria-in-type-2-diabetes-with-chronic-kidney-disease-100643970","NCT07667517","Finerenone for Regression of Albuminuria in Type 2 Diabetes With Chronic Kidney Disease","Efficacy and Safety of Finerenone for the Early Regression of Albuminuria in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial.","Inclusion Criteria:\n\n* 1\\. Age \\>= 18 years at the time of signing informed consent, male or female.\n* 2\\. Type 2 diabetes mellitus.\n* 3\\. Chronic kidney disease meeting BOTH of the following: eGFR (CKD-EPI) \\>= 30 mL\u002Fmin\u002F1.73 m\\^2, and UACR 30-2000 mg\u002Fg (mean of 3 measurements).\n* 4\\. Serum potassium \\\u003C= 5.0 mmol\u002FL.\n* 5\\. On a maximum tolerated dose of an ACE inhibitor or ARB for at least 90 days.\n* 6\\. Treatment with an SGLT-2 inhibitor, GLP-1 receptor agonist, or other agents affecting UACR is permitted, but the type and dose must be stable for at least 30 days before screening.\n\nExclusion Criteria:\n\n* 1\\. Type 1 diabetes, other specific types of diabetes, or gestational diabetes.\n* 2\\. HbA1c \\>= 8.0%.\n* 3\\. On renal replacement therapy.\n* 4\\. Acute kidney injury within 180 days before the screening visit.\n* 5\\. Hepatic impairment (Child-Pugh class C).\n* 6\\. Blood pressure \\> 160\u002F100 mmHg, or systolic blood pressure \\\u003C 90 mmHg, at the screening visit.\n* 7\\. Bilateral renal artery stenosis.\n* 8\\. Known hypersensitivity to the study drug (active substance or excipients).\n* 9\\. Treatment with finerenone within 60 days before screening.\n* 10\\. Stroke, transient ischemic attack, acute coronary syndrome (myocardial infarction, CABG, PCI), or hospitalization for worsening heart failure within 90 days before the screening visit.\n* 11\\. NYHA class II-IV heart failure.\n* 12\\. Addison's disease.\n* 13\\. Gastrointestinal surgery that may affect drug absorption.\n* 14\\. Any other history, condition, therapy, or uncontrolled concomitant disease that makes the participant unsuitable for the study or unlikely to complete it (e.g., active malignancy or other disease with life expectancy \\\u003C 12 months).\n* 15\\. Treatment with a strong CYP3A4 inhibitor (e.g., itraconazole, clarithromycin, ketoconazole, ritonavir, nelfinavir, cobicistat, telithromycin, nefazodone), a strong CYP3A4 inducer (e.g., carbamazepine, phenytoin, phenobarbital, St. John's wort), or a moderate CYP3A4 inducer (e.g., efavirenz) that cannot be discontinued for at least 7 days before randomization.\n* 16\\. Treatment with another mineralocorticoid receptor antagonist (e.g., spironolactone, eplerenone, esaxerenone) or a potassium-sparing diuretic (e.g., amiloride, triamterene) that cannot be discontinued for at least 60 days before the screening visit.\n* 17\\. Biopsy-confirmed non-diabetic kidney disease (e.g., IgA nephropathy).\n* 18\\. Immunosuppressive therapy, or glucocorticoid use by any route other than topical or inhaled, within the past 180 days.\n* 19\\. Participation in another interventional clinical study or use of any investigational product within 90 days before randomization.\n* 20\\. History of alcohol or drug abuse.\n* 21\\. Women of childbearing potential who are pregnant, breastfeeding, intend to become pregnant, or are not using adequate contraception during the study.\n* 22\\. Any other condition deemed by the investigator to make the participant unsuitable for the study.",{"count":48,"type":20},148,[23],"This is a multicenter, randomized, double-blind, placebo-controlled clinical trial evaluating the efficacy and safety of finerenone, a nonsteroidal mineralocorticoid receptor antagonist, for the early regression of albuminuria in adults with type 2 diabetes mellitus and chronic kidney disease (eGFR \\>= 30 mL\u002Fmin\u002F1.73 m\\^2 and UACR 30-2000 mg\u002Fg) who are already receiving a maximum tolerated dose of an ACE inhibitor or ARB. A total of 148 participants are randomized 1:1, stratified by baseline UACR (\\\u003C300 vs \\>=300 mg\u002Fg), to oral finerenone (10 or 20 mg once daily, titrated by serum potassium and eGFR) or matching placebo, on top of standard background therapy, for 180 days, followed by a 30-day off-treatment follow-up. Albuminuria regression is defined as both an improvement in Kidney Disease: Improving Global Outcomes albuminuria category, from A3 to A2 or A1, or from A2 to A1, and a more than 30% reduction in urinary albumin-to-creatinine ratio from baseline. The outcome will be reported as the percentage of participants meeting this definition at Day 180.",[26,52,53],"Type 2 Diabetes Mellitus (T2DM)","Chronic Kidney Diseases",[55,56,57,58,59],"Finerenone","Nonsteroidal mineralocorticoid receptor antagonist","Urine albumin-to-creatinine ratio","KDIGO","Albuminuria regression","NOT_YET_RECRUITING","2026-06-19",{"date":63,"type":31},"2026-06-25",{"date":65,"type":20},"2026-07-01",{"date":67,"type":20},"2027-12-31",{"name":69,"class":38},"First Affiliated Hospital of Zhejiang University",13,{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":78,"enrollmentInfo":79,"targetDuration":4,"studyType":21,"phases":81,"briefSummary":83,"conditions":84,"keywords":86,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":39},"100606399","phase-2-targeting-the-pathophysiology-of-sickle-cell-related-kidney-disease-using-the-sglt2-inhibitors-empagliflozin-100606399","NCT07175051","Targeting the Pathophysiology of Sickle Cell-Related Kidney Disease Using the SGLT2 Inhibitors, Empagliflozin","EMPA-CKD","Inclusion Criteria:\n\n* Documentation of SCA genotype (HbSS or HbSβ0-thalassemia)\n* Albuminuria defined by a UACR of 100 - 2,000 mg\u002Fg creatinine at the screening\n* Hemoglobin (Hb) ≥ 5.5 g\u002FdL during screening\n* For participants taking Endari, the dose of Endari must be stable for at least one month prior to signing the ICF and with no anticipated need for dose adjustments during the study\n* For participants on crizanlizumab or chronic red blood cell transfusions, the therapy must have started at least 3 months prior to consent\n* For participants taking an angiotensin converting enzyme inhibitor (ACEi) or angiotensin II receptor blocker (ARB), the dose must be stable for at least 3 months prior to signing the ICF and with no anticipated need for dose adjustments during the study, in the opinion of the Investigator\n* Participants must demonstrate regular compliance with clinic visits and outpatient management\n* Participants, if female and of childbearing potential, will use highly effective methods of contraception from study start to 30 days after the last dose of the study drug\n* Participant has provided documented informed consent or assent\n\nExclusion Criteria:\n\n* Concurrent diagnosis of diabetes mellitus\n* Female who is breast feeding, pregnant, or unwilling to use birth control as described in the protocol\n* Prior hypersensitivity or intolerance to a sodium-glucose cotransporter-2 inhibitor (SGLT2i)\n* Active or open leg ankle ulcer\n* Chronic urinary tract infection\n* Hospitalized for sickle cell crisis or other vaso-occlusive event within 14 days prior to signing consent\n* Hepatic dysfunction characterized by alanine aminotransferase (ALT) \\>5× ULN\n* Participants with acute bacterial infection requiring antibiotic use should delay screening\u002Fenrollment until the course of antibiotic therapy has been completed\n* Participants with known active hepatitis A, B, or C or who are known to be human immunodeficiency virus (HIV) positive\n* Moderate to severe CKD (defined by an eGFR \\\u003C 30 mL\u002Fmin\u002F1.73m2, on chronic dialysis, or having received a kidney transplantation)\n* History of malignancy within the past 2 years prior to treatment Day 1 requiring chemotherapy and\u002For radiation (with the exception of local therapy for non-melanoma skin malignancy)\n* History of unstable or deteriorating cardiac or pulmonary disease within 6 months prior to consent including but not limited to the following:\n\n  1. Unstable angina pectoris or myocardial infarction or elective coronary intervention\n  2. Uncontrolled clinically significant arrhythmias\n* Any condition affecting drug absorption, such as major surgery involving the stomach (e.g. bariatric surgery) or small intestine (prior cholecystectomy is acceptable)\n* Participated in another clinical trial of an investigational agent (or medical device) within 30 days or 5 half-lives of agent, whichever is longer, or is currently participating in another trial of an investigational agent or medical device)\n* Medical, psychological, or behavioral conditions, which, in the opinion of the Investigator, may preclude safe participation, confound study interpretation, interfere with compliance, or preclude informed consent\n* Contraindication to MRI (certain pacemakers, electronic implants, shrapnel in the eyes, or certain intracranial aneurysm clips)","60 Years",{"count":80,"type":20},20,[82],"PHASE2","Sickle cell anemia (SCA) is an inherited red blood disorder. The kidneys are among the most commonly affected organ systems in SCA. The Food and Drug Administration (FDA) has approved empagliflozin as a treatment to reduce the decline of kidney function in those with kidney disease. The proposed research study aims to determine whether empagliflozin can prevent the progression of kidney dysfunction in patients with sickle cell anemia (SCA) who are at high risk of developing advanced chronic kidney disease (CKD).",[85,26],"Sickle Cell Anemia (HbSS, or HbSβ-thalassemia0)",[87,88],"Empa-CKD","Sickle Cell-Related Kidney Disease","2026-05-15",{"date":91,"type":31},"2026-05-19",{"date":93,"type":31},"2026-04-08",{"date":95,"type":20},"2030-10",{"name":97,"class":38},"University of Illinois at Chicago",{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":104,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":106,"enrollmentInfo":107,"targetDuration":4,"studyType":109,"phases":4,"briefSummary":110,"conditions":111,"keywords":121,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":39},"100506981","prevalence-incidence-and-risk-signature-of-chronic-kidney-disease-in-sub-saharan-africa-100506981","NCT05881447","Prevalence, Incidence and Risk Signature of Chronic Kidney Disease in Sub-Saharan Africa","Prevalence, Incidence and Risk Signature of Chronic Kidney Disease in a Primary Care Setting in Semirural Sub-Saharan Africa","RenalTWO","Inclusion Criteria:\n\nall adult patients (≥18 years) attending the outpatients department of the Bagamoyo district hospital (BDH) or the associated Fukayosi and Yombo dispensary\n\nExclusion Criteria:\n\n* \\\u003C18 years of age\n* not living in the BDH catchment area\n* not of African decent\n* not willing to come back for follow-up visits","99 Years",{"count":108,"type":20},1200,"OBSERVATIONAL","Chronic kidney disease (CKD) is associated with increased cardiovascular morbidity and mortality. The prevalence of CKD is increasing worldwide and is assumed to also dramatically increase in Sub-Saharan Africa (SSA). Key shortcomings of available data on CKD in SSA are as follows: (i) Available data are based on single measurements and, therefore, cannot distinguish between harmless transient deterioration in kidney function and chronic kidney damage; (ii) Accurate information regarding renal protein loss, an important and early marker of kidney disease, is lacking; (iii) Cardiovascular risk factors for CKD, such as obesity, hypertension and diabetes, are often not searched for. Likewise non-classic potential risk factors, such as endemic infectious diseases, socioeconomic status and lifestyle have not been consistently recorded; (iv) Information to interrogate linked interaction over time between risk factors and development of CKD is unavailable. With this project, situated in a region representative of semi-rural SSA, we aim to fill this knowledge gap and (i) establish guideline conform prevalence data of CKD and its major cardiovascular risk factors, as well as (ii) prospectively define the incidence of cardiovascular- and non-classic risk factors of CKD. The data from (i) and (ii) is used to develop predictive models. A prospective cohort of 1200 individuals in a primary care facility will serve as study population. The population is representing a society in transition from rural to more urban lifestyle. In the pilot study, participants will be followed for one years and undergo the clinical and biomedical testing required to capture CKD and its classic and non-classic risk factors over time.",[53,112,113,114,115,116,117,118,119,26,120],"Type 2 Diabetes Mellitus","Arterial Hypertension","Obesity","Cardiovascular Diseases","HIV Infections","Anemia","Underweight","Infections","Dyslipidemias",[122,123,124,117,125,126,127,128,129],"CKD","Risk factors","Cardiovascular disease","Point of care diagnostics","Albumin creatinine ration (ACR)","Estimated glomerular filtration rate (eGFR)","Kidney Disease: Improving Global Outcomes (KDIGO)","HbA1c","2026-04-23",{"date":132,"type":31},"2026-04-29",{"date":134,"type":31},"2023-06-21",{"date":136,"type":20},"2026-12-31",{"name":138,"class":38},"Swiss Tropical & Public Health Institute",{"id":140,"slug":141,"hasResults":11,"nctId":142,"briefTitle":143,"officialTitle":144,"acronym":145,"eligibilityCriteria":146,"healthyVolunteers":11,"sex":15,"minAge":147,"maxAge":16,"enrollmentInfo":148,"targetDuration":4,"studyType":21,"phases":150,"briefSummary":151,"conditions":152,"keywords":156,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":161,"startDateStruct":163,"completionDateStruct":164,"leadSponsor":166,"locationsCount":39},"100624098","phase-4-efficacy-and-safety-of-sodium-glucose-cotransporter-2-inhibitors-in-adolescents-with-early-stages-of-chronic-kidney-disease-100624098","NCT07405216","Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Adolescents With Early Stages of Chronic Kidney Disease","Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Adolescents With Persistent Albuminuria: A Randomized Controlled Clinical Trial","IECA-MEX","Inclusion Criteria:Age 14-18 years\n\nResidence in Aguascalientes\n\nPersistent albuminuria (ACR \\>30 and \\\u003C300 mg\u002Fg)\n\nEstimated glomerular filtration rate ≥60 mL\u002Fmin\u002F1.73 m²\n\nNo identifiable secondary cause (e.g., lupus, diabetes mellitus)\n\nRenal biopsy showing adaptive podocytopathy or perihilar focal segmental glomerulosclerosis -\n\nExclusion Criteria:\n\nHypoalbuminemia\n\nNephrotic syndrome\n\nPersistent macroalbuminuria (ACR \\>300 mg\u002Fg)\n\nSecondary causes of CKD, including congenital anomalies of the kidney and urinary tract or polycystic kidney disease -","14 Years",{"count":149,"type":20},200,[23],"Chronic kidney disease (CKD) is highly prevalent in the state of Aguascalientes, Mexico, particularly among adolescents and young adults. Epidemiologic and histologic studies suggest that this burden is largely driven by reduced nephron endowment of prenatal origin, leading to compensatory glomerular hyperfiltration, adaptive podocytopathy, and persistent albuminuria at early stages of disease.\n\nSodium-glucose cotransporter-2 inhibitors (SGLT2i) have demonstrated nephroprotective effects in adult populations with CKD, including reductions in albuminuria and slowing of disease progression, independent of diabetes status. However, no randomized controlled trials have evaluated the efficacy and safety of SGLT2 inhibitors in adolescents with early-stage CKD and persistent albuminuria.\n\nThis randomized, double-blind, placebo-controlled clinical trial aims to evaluate whether treatment with an SGLT2 inhibitor reduces albuminuria in adolescents aged 14 to 18 years with persistent microalbuminuria (albumin-to-creatinine ratio 30-300 mg\u002Fg) and preserved kidney function. Participants will be randomized in a 2:1 ratio to receive dapagliflozin 10 mg daily or placebo for six months. The primary outcome is the change in urinary albumin-to-creatinine ratio from baseline to six months. Secondary outcomes include changes in estimated glomerular filtration rate and safety outcomes.",[153,26,154,155],"Chronic Kidney Disease (Mild to Moderate)","Adolescent","Sodium Glucose Co-Transporter 2 Inhibitors",[157,158,159],"Chronic kidney disease","Persistent albuminuria","sodium glucose co-transporter 2 inhibitors","2026-04-22",{"date":162,"type":31},"2026-04-27",{"date":130,"type":31},{"date":165,"type":20},"2027-10-30",{"name":167,"class":38},"Centenario Hospital Miguel Hidalgo",{"id":169,"slug":170,"hasResults":11,"nctId":171,"briefTitle":172,"officialTitle":173,"acronym":174,"eligibilityCriteria":175,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":176,"enrollmentInfo":177,"targetDuration":4,"studyType":109,"phases":4,"briefSummary":179,"conditions":180,"keywords":186,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":190,"lastUpdatePostDateStruct":191,"startDateStruct":193,"completionDateStruct":195,"leadSponsor":197,"locationsCount":70},"100432824","diabetic-nephropathy-in-people-with-diabetes-prevalence-and-predictive-factors-100432824","NCT04916132","Diabetic Nephropathy in People With Diabetes. Prevalence and Predictive Factors","Biopsy-proven Diabetic Nephropathy in People With Type 2 Diabetes. Prevalence and Predictive Factors","PRIMETIME2","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Written informed consent\n* Diagnosis with T2DM according to the American diabetes Association (20)\n* eGFR \\>30 mL\u002Fmin\u002F1.73 m2 (maximum six months old)\n* urine-albumin\u002Fcreatinine-ratio (uACR) \\> 700 mg\u002Fg or 24 hours urine albumin \\>700 mg on more than one measurement\n\nExclusion Criteria:\n\n* Signs of acute kidney failure according to the KDIGO classification (21) at the time for kidney biopsy or the last 6 months before kidney biopsy\n* Factors that increases the risk of complications due to kidney biopsy:\n\n  * Hemoglobin \\\u003C 6 mmol\u002FL\n  * INR \\>1,4 at the time for biopsy\n  * Platelet count \\\u003C 100 x 109\u002Fl\n  * Uncontrolled high blood pressure (defined as systolic blood pressure \\> 160 mmHg and\u002For diastolic blood pressure \\> 100 mmHg)\n  * Only one functioning kidney\n  * Evidence of urinary tract obstruction or hydronephrosis at the time of biopsy\n  * Multiple bilateral kidney cysts\n  * Kidney infection, peri-renal infection, or cutaneous infection that overlies the kidney at time for biopsy\n  * Unwilling to receive blood transfusion\n  * Unable to lie flat in bed six hours after biopsy\n  * Any other contra-indications for percutaneous kidney biopsy according to local clinical guidelines\n* Unable to understand written and oral information\n* Kidney transplant recipient\n* Previous medical kidney biopsy\n* Women who are pregnant or planning to become pregnant before the kidney biopsy is performed\n* Treatment with Marcoumar (all other anticoagulants are accepted)\n* High thromboembolic risk combined with held in anticoagulation therapy according to the report \"Perioperative regulation of antithrombotic treatment\" (PRAB) (22)\n\n  * mechanical heart valve\n  * atrial fibrillation AND CHA2DS2-VASc\\> 5 and\u002For stroke within the last three months\n  * recurrent venous thromboembolism OR venous thromboembolism within the last three months\n  * less than 6 weeks after uncomplicated Acute Coronary Syndrome (ACS) with or without revascularization (Percutaneous Coronary Intervention (PCI)) with Bare Metal Stents (BMS) or Coronary Artery Bypass Grafting (CABG))\n  * less than 3 months after uncomplicated ACS with revascularization (PCI with Drug Eluting Stent (DES))\n  * less than 9-12 months after complicated ACS (e.g. reinfarction or stent thrombosis)\n  * less than 1 month after revascularization in individuals with stable Coronary Artery Disease (CAD) (PCI with BMS or CABG)\n  * less than 3 months after revascularization in individuals with stable CAD (PCI with DES)\n  * less than 3 months after stroke, or Transient Ischemic Attack (TIA)\n* Inability to withdraw nonsteroidal anti-inflammatory drugs (NSAID) 7 days before biopsy\n\nIf a participant meets one or more exclusion criteria, that are reversible, the participant can be rescreened later on, to evaluate whether or not the participant now is qualified for participation.","120 Years",{"count":178,"type":20},300,"a prospective, observational, multi-center study with a cohort of 300 patients with Type 2 diabetes and macroalbuminuria. Prospectively we will collect kidney biopsies and analyse the transciptome of the kidney tissue and other biomarkers from blood, faeces, urine, proteomic- and metabolomic profiles and DNA-variants. Thereby we hope to be able to discover molecular and clinical profiles, that can help us in the diagnosis of DKD, and to identify different risks of progression that can benefit from different forms of personalized treatment.",[53,26,181,182,183,184,185],"Diabetic Kidney Disease","Diabetic Nephropathies","Diabetes type2","Molecular Sequence Variation","Kidney Biopsy",[187,188,189],"diabetic nephropaty","precision medicine","kidney biopsy","2025-12-17",{"date":192,"type":31},"2025-12-24",{"date":194,"type":31},"2021-08-10",{"date":196,"type":20},"2043-12-31",{"name":198,"class":38},"Herlev Hospital",{"id":200,"slug":201,"hasResults":11,"nctId":202,"briefTitle":203,"officialTitle":204,"acronym":205,"eligibilityCriteria":206,"healthyVolunteers":207,"sex":15,"minAge":208,"maxAge":16,"enrollmentInfo":209,"targetDuration":4,"studyType":109,"phases":4,"briefSummary":211,"conditions":212,"keywords":230,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":254,"lastUpdatePostDateStruct":255,"startDateStruct":257,"completionDateStruct":259,"leadSponsor":261,"locationsCount":39},"100420250","pediatric-hypertension-and-the-renin-angiotensin-system-phrase-100420250","NCT04752293","Pediatric Hypertension and the Renin-Angiotensin SystEm (PHRASE)","Pediatric Hypertension and the Renin-Angiotensin SystEm (PHRASE): The Role of Angiotensin-(1-7) in Hypertension and Hypertension-Induced Heart and Kidney Damage","PHRASE","INCLUSION CRITERIA: HYPERTENSION COHORT\n\n* 7-18 years of age at time of enrollment\n* Confirmed new diagnosis of primary hypertension: no identifiable secondary cause, referred to hypertension or nephrology clinic\n\n  * Age \\\u003C13 years: BP ≥95th %ile or ≥130\u002F80 mmHg (whichever is lower)\n  * Age ≥13 years: BP ≥130\u002F80 mmHg\n* Participants and their caregivers must be willing and able to commit to completing the study assessments\n\nEXCLUSION CRITERIA: HYPERTENSION COHORT\n\n* \\\u003C7 years or \\>18 years of age at time of enrollment\n* BP confirmed as normal or in the elevated BP category based on ≥3 prior office BP measurements on separate days;\n\n  * Age \\\u003C13 years: BP \\\u003C95th %ile or \\\u003C130\u002F80 mmHg (whichever is lower)\n  * Age ≥13 years: BP \\\u003C130\u002F80 mmHg\n* A confirmed secondary cause of hypertension\n* Confounding medical condition (heart or kidney disease \\[except hypertension-associated heart changes on echocardiogram or albuminuria\\], vascular\u002Finflammatory disease, or diabetes)\n* Inability to complete study assessments\n* Non-English\u002FSpanish speakers\n* Current pregnancy\n* Ward of the State\n\nINCLUSION CRITERIA: CONTROL COHORT\n\n* 7-18 years of age at time of enrollment\n* Normal BP based on ≥3 prior office BP measurements on separate days;\n\n  * Age \\\u003C13 years: BP \\\u003C90th %ile or \\\u003C120\u002F80 mmHg (whichever is lower)\n  * Age ≥13 years: BP \\\u003C120\u002F80 mmHg\n* Participants and their caregivers must be willing and able to commit to completing the study assessments\n\nEXCLUSION CRITERIA: CONTROL COHORT\n\n* \\\u003C7 or \\>18 years of age at time of enrollment\n* Elevated BP or hypertension, based on ≥3 prior office BP measurements on separate days:\n\n  * Age \\\u003C13 years: BP ≥90th %ile or ≥120\u002F80 mmHg (whichever is lower)\n  * Age ≥13 years: BP ≥120\u002F80 mmHg\n* History of elevated BP or hypertension\n* Current use of BP-lowering medications\n* Confounding medical condition (heart or kidney disease, vascular\u002Finflammatory disease, or diabetes)\n* Inability to complete study assessments\n* Non-English\u002FSpanish speakers\n* Current pregnancy\n* Ward of the State",true,"7 Years",{"count":210,"type":20},125,"Studying the causal roles of components of the renin-angiotensin-aldosterone system (including angiotensin-(1-7) (Ang-(1-7)), angiotensin-converting enzyme 2 (ACE2), Ang II, and ACE), uric acid, and klotho in pediatric hypertension and related target organ injury, including in the heart, kidneys, vasculature, and brain. Recruiting children with a new hypertension diagnosis over a 2-year period from the Hypertension and Pediatric Nephrology Clinics affiliated with Brenner Children's Hospital at Atrium Health Wake Forest Baptist and Atrium Health Levine Children's Hospital. Healthy control participants will be recruited from local general primary care practices. Collecting blood and urine samples to analyze components of the renin-angiotensin-aldosterone system (Ang-(1-7), ACE2, Ang II, ACE), uric acid, and klotho, and measuring blood pressure, heart structure and function, autonomic function, vascular function, and kidney function at baseline, year 1, and year 2. Objectives are to investigate phenotypic and treatment response variability and to causally infer if Ang-(1-7), ACE2, Ang II, ACE, uric acid, and klotho contribute to target organ injury due to hypertension.",[213,214,215,216,217,218,219,220,221,222,223,224,225,226,227,228,229,26],"Hypertension","Left Ventricular Hypertrophy","Left Ventricular Dysfunction","Left Atrial Dilatation","Left Ventricular Diastolic Dysfunction","Kidney Diseases","Kidney Injury","Kidney Dysfunction","Sodium Urine High","Blood Pressure Disorders","Uric Acid Retention","Angiotensin Hypertension","Autonomic Dysfunction","Autonomic Imbalance","Pediatric Kidney Disease","Pediatric Obesity","Proteinuria",[231,232,213,233,234,214,26,235,236,237,238,239,240,241,242,243,244,245,246,247,217,219,248,249,228,250,251,252,253],"High Blood Pressure","Elevated Blood Pressure","Pediatric Hypertension","Target Organ Damage","Uric Acid","Klotho","Fibroblast Growth Factor 23","Renin-Angiotensin-Aldosterone System","Renin-Angiotensin System","Angiotensin-(1-7)","Angiotensin II","Angiotensin-Converting Enzyme 2","Angiotensin-Converting Enzyme","Causal Inference","Causal Mediation Analysis","Sensitivity Analysis","Predictive Analysis","Heart Rate Variability","Sodium","Lifecourse","Kidney Function","Ambulatory Blood Pressure Monitoring","Echocardiogram","2025-12-04",{"date":256,"type":31},"2025-12-11",{"date":258,"type":31},"2021-05-19",{"date":260,"type":20},"2026-12",{"name":262,"class":38},"Wake Forest University Health Sciences",{"id":264,"slug":265,"hasResults":11,"nctId":266,"briefTitle":267,"officialTitle":268,"acronym":269,"eligibilityCriteria":270,"healthyVolunteers":11,"sex":15,"minAge":271,"maxAge":4,"enrollmentInfo":272,"targetDuration":4,"studyType":21,"phases":274,"briefSummary":276,"conditions":277,"keywords":284,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":290,"lastUpdatePostDateStruct":291,"startDateStruct":293,"completionDateStruct":295,"leadSponsor":297,"locationsCount":39},"100606246","algae-effects-in-markers-of-cardiovascular-risk-and-gut-microbiome-100606246","NCT07173062","Algae Effects in Markers of Cardiovascular Risk and Gut Microbiome","Algae Effects in Markers of Cardiovascular Risk and Gut Microbiome: a Placebo-controlled Randomized Double-blind Trial","CALGUT","Inclusion Criteria:\n\n* ≥50 years\n* BMI ≥20 kg\u002Fm2\n* History of stroke, coronary artery disease, myocardial infarction, peripheral artery disease, chronic kidney disease (eGFR \\\u003C75 ml\u002Fmin at least for 3 months), albuminuria \\>300 mg\u002Fg, or diabetes mellitus\n* No antibiotics in the previous 30 days\n* If a woman, she must be a woman of non-childbearing potential. That is, she must be:\n\n  * Surgically sterilized (e.g. underwent hysterectomy, bilateral salpingectomy or bilateral oophorectomy);\n  * Clinically diagnosed infertile;\n  * In a post-menopausal state, defined as no menses for 12 months without an alternative medical cause.\n* A woman patient of childbearing potential must have a negative serum pregnancy test at Visit 0 (Day 0) and must agree to use consistently and correctly (from 28 days prior to first study treatment administration until at least 7 days after last study treatment administration) one of the following highly effective methods of contraception:\n\n  * Abstinence of heterosexual intercourse (when this is in line with preferred and usual lifestyle of the subject);\n  * Progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable);\n  * Combined (oestrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, transdermal);\n  * Intrauterine device;\n  * Intrauterine hormone-releasing system;\n  * Bilateral tubal occlusion;\n  * Vasectomized partner, who has received medical assessment of the surgical success, or clinically diagnosed infertile partner.\n\nExclusion Criteria:\n\n* Unwilling to sign the informed consent form (if the patient wants to participate but cannot sign for any reason, then a third-person testimony may sign\u002Fcomplete the informed consent form on the patient's behalf).\n* Involvement in the planning and\u002For conduct of the study (applies to both Investigator staff and\u002For staff at the study site).\n* Participation in another clinical study with an investigational product during the last month.\n* In participants recruited at Unidade Local de Saúde de São João, the exclusion criteria applied is estimated Glomerular Filtration Rate (eGFR) \\\u003C30 ml\u002Fmin\u002F1.73m2 estimated with the CKD-EPI (2021) formula or dialysis. For participants recruited at community, this exclusion criteria is adapted for diagnosis of end-stage renal disease or dialysis (no need to quantify the eGFR).","50 Years",{"count":273,"type":20},150,[275],"NA","The Western diet, rich in fat and sugar, contributes to cardiovascular risk and alters the body metabolism, specifically through the modulation of the microbiome. Microbiome is considered the \"second genome\", functioning as an endocrine-like organ. Gut microbiota-derived metabolites, namely trimethylamine- N-oxide and short-chain fatty acids have been associated with atherosclerosis, vascular and cardiac diseases. Regarding trimethylamine- N-oxide, its association with cardiovascular disease is positive and dose-dependent. In contrast, short-chain fatty acids have been positively associated with the improvement of cardiovascular health.\n\nAlgae probiotics can modulate gut microbiome, stimulating the growth of commensal micro-organisms with health benefits. Previous studies suggested that Spirulina Arthrospira platensis supplementation could improve blood lipid levels and lower blood pressure, revealing anti-inflammatory and antioxidant roles. Other probiotics that could be beneficial to gut microbiota are macroalgae or seaweed. Macroalgae are a rich source of components which may prompt bacterial diversity and abundance.\n\nThe present prospective, randomized, three-armed parallel trial aims to generate good-quality evidence about the potential health effects and impact of Spirulina Arthrospira platensis (microalgae) and Gelidium corneum (macroalgae) supplements in humans. These participants will undergo 3 clinical evaluations: 2 before the beginning of micro- and macro-algae supplementation and the last one after 20 weeks of supplementation. The evaluation includes a vascular, nutritional and physical activity assessment, as well as blood, urine, saliva and stool collection for quantification of plasma biomarkers, oral and gut microbiota analysis, respectively.",[278,279,280,281,282,283,26],"Stroke","Coronary Arterial Disease (CAD)","Myocardial Infarction (MI)","Diabetes Mellitus","Peripheral Artery Disease (PAD)","Chronic Kidney Disease(CKD)",[285,286,287,288,289],"Spirulina Arthrospira platensis","Gelidium corneum","Trimethylamine- N-oxide (TMAO)","Short-Chain Fatty Acids (SCFA)","Cardiovascular risk (CVR)","2025-09-12",{"date":292,"type":31},"2025-09-15",{"date":294,"type":31},"2025-03-11",{"date":296,"type":20},"2026-08",{"name":298,"class":38},"Universidade do Porto",{"id":300,"slug":301,"hasResults":11,"nctId":302,"briefTitle":303,"officialTitle":304,"acronym":305,"eligibilityCriteria":306,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":307,"targetDuration":4,"studyType":21,"phases":309,"briefSummary":310,"conditions":311,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":317,"lastUpdatePostDateStruct":318,"startDateStruct":320,"completionDateStruct":322,"leadSponsor":324,"locationsCount":326},"100527397","phase-2-prevention-of-chronic-kidney-diseasecdk-progression-in-type-1-diabetes-with-long-term-use-of-sodium-glucose-cotransporter-inhibitors-avoiding-kidney-hypoxia-100527397","NCT06147232","Prevention of Chronic Kidney Disease(CDK) Progression in Type 1 Diabetes With Long Term Use of Sodium-Glucose-coTransporter Inhibitors Avoiding Kidney hypOxia","Prevention of CKD Progression in Type 1 Diabetes With Long Term Use of SGLTi Avoiding Kidney hypOxia(PLUTO)","PLUTO","Inclusion Criteria:\n\n1. Persons ≥ 18 years of age with a diagnosis of type 1 diabetes (age at onset \\\u003C40 years; permanent insulin treatment initiated within 1 year of diagnosis)\n2. Albuminuria: UACR \\> 100 mg\u002Fg (in ≥2 out 3 morning spot urine collections prior to randomization)\n3. estimated Glomerular Filtration Rate(eGFR) ≥25 and \\\u003C 75 ml\u002Fmin\u002F1.73m2\n4. Participants must be on stable renin-angiotensin system blocking treatment 4 weeks before start of study drug and throughout study duration.\n5. Able to understand the written participant information and give informed consent\n\nExclusion Criteria:\n\n1. Non-diabetic kidney disease indicated by medical history and\u002For laboratory findings.\n2. eGFR\\\u003C 25 ml\u002Fmin\u002F1.73m2, dialysis or kidney transplantation.\n3. Previous diabetic ketoacidosis, except at debut.\n4. Dysregulated diabetes (HbA1c \\> 85 mmol\u002Fmol)\n5. Decreased awareness or unawareness\n6. Pregnancy, lactating or with a wish of pregnancy within the next year\n7. Low carbohydrate diet\n8. Receiving therapy with an SGLT inhibitor within 8 weeks prior to enrolment or previous intolerance of an SGLT inhibitor.\n9. New York Heart Association (NYHA) class IV Congestive Heart Failure at the time of enrolment\n10. Myocardial infarction, unstable angina, stroke or transient ischemic attack within 12 weeks prior to enrolment\n11. The receipt of any investigational product 90 days prior to this trial\n12. Unable to participate in study procedures\n13. Any clinically significant disorder, except for conditions associated with type 1 diabetes, which in the Investigators opinion could interfere with the results of the trial\n14. Participation in another intervention study\n15. Exclusion criteria for MRI: known claustrophobia, known chronic lung disease, surgery within past 6 weeks or having foreign bodies of metal in the body (e.g. pacemaker, metal plates, metal screws)\n16. Recurrent urogenital infections.",{"count":308,"type":20},69,[82],"Background: Sodium-glucose-cotransporter (SGLT) inhibition has been observed to reduce risk of cardiovascular events and kidney failure in persons with type 2 diabetes. People with type 1 diabetes also have increased risk of cardiovascular and kidney disease, and may benefit from SGLT-inhibition. The exact mechanism of how SGLT-inhibition benefits the kidneys are yet unknown. Change in renal hypoxia may be a factor.\n\nObjective: The primary aim of this study is to assess the effects of 12 weeks SGLT-1 and 2 inhibition on renal oxygenation in persons with type 1 diabetes and chronic kidney disease.\n\nFurther aims are to study if renal oxygen consumption and response to SGLT-inhibition differs between people of African-Caribbean or Northern European decent.\n\nAdditionally effects on left ventricular ejection fraction, kidney function and biomarkers in blood and urine will be explored.\n\nMethod: 12 weeks treatment with oral sotagliflozin or matching placebo as intervention. Kidney oxygenation and perfusion parameters and left ventricular ejection fraction will be assessed by functional magnetic resonance imaging. Kidney function and biomarkers will be assessed according to local hospital laboratory guidelines.\n\nDesign: Randomized, double-blinded, placebo-controlled, cross over intervention study.\n\nStudy population: 69 persons with type 1 diabetes and diabetic kidney disease with albuminuria will be included, 39 at Steno Diabetes Center Copenhagen, 30 at King's College London.\n\nEndpoints: Primary end-point: Change from 0 to 12 weeks in dynamic R2\\*-weighted signal after treatment with sotagliflozin compared to placebo. Secondary endpoints: Change from 0 to 12 weeks with sotagliflozin compared with placebo on renal perfusion, renal artery flow, renal oxygen consumption, renal parenchymal triglyceride fraction, renal fibrosis, left ventricular ejection fraction, urinary albumin-creatinin ratio, ketone bodies, erythropoietin, pro brain natriuretic peptide, and plasma- and urine inflammation- and fibrosis biomarkers as well as difference after 12 weeks treatment in glomerular filtration rate.\n\nTimeframe: Inclusion of patients from february 2024. Last visit september 2025. Presentation spring 2026, publication fall 2026.",[312,182,313,26,314,315,316],"Nephropathy","Diabetes Mellitus, Type 1","Diabetic Complications Renal","Diabetic Complications Cardiovascular","Hypoxia","2025-01-22",{"date":319,"type":31},"2025-01-27",{"date":321,"type":20},"2025-02",{"date":323,"type":20},"2027-05",{"name":325,"class":38},"Steno Diabetes Center Copenhagen",2,{"id":328,"slug":329,"hasResults":11,"nctId":330,"briefTitle":331,"officialTitle":331,"acronym":4,"eligibilityCriteria":332,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":333,"targetDuration":4,"studyType":109,"phases":4,"briefSummary":334,"conditions":335,"keywords":338,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":340,"lastUpdatePostDateStruct":341,"startDateStruct":343,"completionDateStruct":345,"leadSponsor":347,"locationsCount":4},"100563876","clinical-findings-and-albuminuria-as-predictors-of-acute-kidney-injury-in-patients-with-acute-heart-failure-100563876","NCT06621862","Clinical Findings and Albuminuria as Predictors of Acute Kidney Injury in Patients With Acute Heart Failure","Inclusion Criteria:\n\n* All patients of 18 years and older who will be admitted to the ICU with acute heart failure (acute heart failure is defined according ESC guidelines 2021 which include Heart Failure with Reduced Ejection Fraction (HFrEF) EF \\<40% . Mid-Range Ejection Fraction (HFmrEF)(41 -46 %) , Preserved Ejection Fraction (HFpEF) EF ≥ 50%.\n\nExclusion Criteria:\n\n* patients under the age of 18.\n\nPatients with known chronic kidney disease (CKD) before ICU admission (CKD is defined as the presence of kidney damage or an estimated glomerular filtration rate (eGFR) less than 60 ml\u002Fmin\u002F1.73 mt2, persisting for 3 months or more, and or albuminuria more than 3.5 mg\u002Fmmol (12)\n\nsevere UTI",{"count":19,"type":20},"assess the predictive value of clinical examination and proteinuria as early measures for acute kidney injury (AKI) in patient with acute heart failure and assessing their prognostic value as measures for mortality during hospital stay",[336,337,26],"Heart Failure","Acute Kidney Injury",[339,337,26],"Heart failure","2024-09-28",{"date":342,"type":31},"2024-10-01",{"date":344,"type":20},"2024-09-30",{"date":346,"type":20},"2026-09-30",{"name":348,"class":38},"Hagar Mahmoud Hammad"]